Trial Profile
A trial to evaluate the combination of sorafenib, bevacizumab, and low-dose cyclophosphamide in children with solid tumors to find incidence of pneumothorax
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jun 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cyclophosphamide (Primary) ; Sorafenib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 03 Jun 2016 New trial record